| Literature DB >> 26232702 |
Chaoran Xu1, Wei He2, Yaqi Lv1, Chao Qin1, Lingjia Shen3, Lifang Yin4.
Abstract
A prodrug-based nanosystem obtained by formulating prodrug and nanotechnology into a system is one of the most promising strategies to enhance drug delivery for disease treatment. Herein, we report a new nanosystem based on HA-PTX conjugates (HA-PTX Ns), which penetrated across cell membranes into cytosol, thus enhancing paclitaxel (PTX) delivery. HA-PTX Ns were successfully obtained based on HA-PTX, and their average particle size was approximately 200 nm. Importantly, unlike other prodrug-based nanosystems, HA-PTX Ns obtained cellular entry without entrapment within the lysosomal-endosomal system by using pathways including clathrin-mediated endocytosis, microtubule-associated internalization, macropinocytosis and cholesterol-dependence. Due to significant accumulation in tumors, HA-PTX Ns had more than a 4-fold decrease in tumor volume on day 14 in contrast with PTX alone. In conclusion, HA-PTX Ns could enter cells, bypass the lysosomal-endosomal system and improve PTX delivery.Entities:
Keywords: Adipic acid dihydrazide (PubChem CID: 66117); Antitumor activity; Carbodiimide hydrochloride (PubChem CID: 15908); Cytosolic delivery; Diphenylphosphinic chloride (PubChem CID: 73910); Fluorescein isothiocyanate (PubChem CID: 18730); IR783 (PubChem CID: 46873808); Internalization pathway; MTT (PubChem CID: 16218671); Nanoparticles; Paclitaxel; Paclitaxel (PubChem CID: 44155032); Prodrug; Pyridine (PubChem CID: 1049); Self-assembly; Succinic anhydride (PubChem CID: 7922); Triethylamine (PubChem CID: 8471)
Mesh:
Substances:
Year: 2015 PMID: 26232702 DOI: 10.1016/j.ijpharm.2015.07.069
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875